Recommandé
Contenu connexe
Similaire à Avaxia Biologics
Similaire à Avaxia Biologics (20)
Plus de MunevarS
Plus de MunevarS (8)
Dernier
Dernier (20)
Avaxia Biologics
- 1. January 17, 2013 Science Shaping our World Barbara S. Fox, PhD, CEO Avaxia Biologics 128 Spring St., Suite 620 Lexington, MA 02421 781-861-0062 x303 bfox@avaxiabiologics.com
- 2. Avaxia Biologics Gut-targeted antibody therapeutics • AVX-470: Oral anti-TNF antibody – Phase 1b clinical trial in patients with active ulcerative colitis • AVX oral antibody platform – Game changing technology expands $50B antibody market • Full pipeline of products – Inflammatory bowel disease – GI acute radiation syndrome – Diabetes – Celiac disease 2
- 3. Avaxia Biologics • Located in Lexington, MA • 13 FTEs • Financing history: $16.4M raised to-date – $5.8M non-dilutive funding • NIH grants, BARDA contract, Mass Life Science Center • Additional $1.7M pending from Department of Defense – $4.1M Series A November 2011 • Cherrystone Angels, Beacon Angels, Boston Harbor Angels, Launchpad Venture Group, Mass Medical Angels, North Country Angels and individuals – $6.5M Series B December 2012 • All Series A angel groups + Golden Seeds, Beta Fund, Granite State Angels, Maine Angels 3
- 4. Avaxia Team Management Team Board of Directors • Barbara Fox, PhD • Barbara Fox, PhD, Avaxia – CEO & Founder • Nada Jain, Golden Seeds • David Dlesk – COO • Henry Kay, Launchpad, BHA • Daniel Tracey, PhD • Chris Kiritsy, Arisaph – VP Research • Rob Manning, Cherrystone • Eileen Bostwick, PhD – VP Development and QC • David Poorvin, PhD, Avaxia • Michael Rivard Scientific & Clin Advisors – VP Corporate Development • Scott Harris, MD • Robert Kamen, PhD – Chief Medical Officer (consulting) • Stephen Sonis, DMD, DMSc • Bruce Sands, MD 4
- 5. Inflammatory Bowel Disease Ulcerative Colitis, Crohn’s Disease • Serious chronic disease with no cure – 2.5 million people, 1 million in US – Abdominal pain, diarrhea, high rate of surgery • Limited therapeutic options – Steroids - High efficacy but poor safety – 5-ASAs – Modest efficacy – Injected anti-TNF monoclonal antibodies • High efficacy, but systemic immunosuppression • Expensive, difficult dosing 5
- 6. AVX-470 for IBD Anti-TNF antibody from colostrum of immunized cows • Stable to digestion in GI tract • Safe for oral delivery (lactose-free) • Minimal systemic exposure • High potency • Low cost of goods • Strong patent position 6
- 7. AVX-470 for Inflammatory Bowel Disease Oral anti-TNF antibody as first line therapy AVX-470 treats IBD in • TNF is validated target mouse model • Deliver to the site of 3.0 inflammation Endoscopy Score 2.5 – Maintain efficacy – Safer due to limited * systemic exposure 2.0 • Position as first-line 1.5 therapy Saline control Steroid AVX-470 Control bovine antibody 7
- 8. 8 AVX-470 for GI Acute Radiation Syndrome Oral anti-TNF antibody stockpiled for defense • US government (BARDA/HHS) is developing countermeasures to protect civilian population in event of nuclear attack • Avaxia awarded $3M BARDA contract July 2011 to develop AVX-470 for GI ARS 100 80 % Survival 60 Mice irradiated with 8Gy total body irradiation Dosed with saline or AVX-470, oral, once per day 40 Survival at day 10 post-irradiation 20 0 Saline AVX-470m 8
- 9. Avaxia Biologics Gut-targeted antibody therapeutics • AVX-470: Oral anti-TNF antibody – Phase 1b clinical trial in patients with active ulcerative colitis • AVX oral antibody platform – Game changing technology expands $50B antibody market • Full pipeline of products – Inflammatory bowel disease – GI acute radiation syndrome – Diabetes – Celiac disease 9